Nimodipine
- Generic Name
- Nimodipine
- Brand Names
- Nimotop, Nymalize
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26N2O7
- CAS Number
- 66085-59-4
- Unique Ingredient Identifier
- 57WA9QZ5WH
- Background
Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Compare...
- Indication
For use as an adjunct to improve neurologic outcome following subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms by reducing the incidence and severity of ischemic deficits.
- Associated Conditions
- Delayed Ischemic Neurological Deficit
- Associated Therapies
- -
FDA approves Azurity Pharmaceuticals' Danziten for CML treatment
FDA approves Azurity Pharmaceuticals’ Danziten (nilotinib), the first nilotinib formulation without mealtime restrictions, for treating chronic myeloid leukaemia (CML). Danziten offers equivalent efficacy to Tasigna with enhanced bioavailability and lower dosage, improving patient adherence by eliminating fasting requirements.
FDA Approves Nymalize in Prefilled ENFit Syringes
FDA approves nimodipine (Nymalize) oral solution in 30 mg/5 mL prefilled ENFit syringes, enhancing safety for subarachnoid hemorrhage patients.
Azurity Pharmaceuticals, Inc. Announces FDA Approval of Nymalize (nimodipine) Oral Solution 30 mg/5 mL Prefilled ENFit® Syringe
Azurity Pharmaceuticals announced FDA approval of Nymalize® (nimodipine) oral solution in a 30 mg/5 mL prefilled ENFit® syringe, aiming to enhance drug administration security. Nymalize offers an alternative to capsule extraction for subarachnoid hemorrhage patients, available in various prefilled syringes and bottles. The ENFit syringe will be available through pharmaceutical wholesalers.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath